February 27, 2015 9:26 AM ET

Biotechnology

Company Overview of Ambit Biosciences Corporation

Company Overview

Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase 3 inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and i...

11080 Roselle Street

San Diego, CA 92121

United States

Founded in 2000

53 Employees

Phone:

858-334-2100

Fax:

858-334-2192

Key Executives for Ambit Biosciences Corporation

Chief Executive Officer and President
Age: 57
Founder
Age: 68
Co-Founder, Chairman of Scientific Advisory Board
Chief Financial Officer and Principal Accounting Officer
Age: 57
General Counsel and Senior Vice President
Age: 48
Compensation as of Fiscal Year 2014.

Ambit Biosciences Corporation Key Developments

Ambit Biosciences Corporation expected to report Fiscal Year 2014 results on February 27, 2015. This event was calculated by Capital IQ (Created on February 21, 2015).

Ambit Biosciences Corporation expected to report Fiscal Year 2014 results on February 27, 2015. This event was calculated by Capital IQ (Created on February 21, 2015).

Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Presentation Date & Speakers: Feb-25-2015, Alan Fuhrman, Chief Financial Officer and Principal Accounting Officer. Feb-26-2015, Michael A. Martino, Chief Executive Officer and President.

Ambit Biosciences Corporation Announces Executive Resignations

Ambit Biosciences Corporation announced resignation of David Bonita, Faheem Hasnain, Jeffrey S. Hatfield, Standish M. Fleming, Mark G. Foletta, Allan P. Marchington, Michael A. Martino, David Parkinson and Isai Peimer as a Board of Directors and any committees thereof, of Ambit.

Similar Private Companies By Industry

Company Name Region
Oligonet, Inc. United States
Neogenix Oncology, Inc. United States
ACT Biotech, Inc. United States
Intercell USA, Inc. United States
Visionsense Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 28, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ambit Biosciences Corporation, please visit www.ambitbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.